Recombinant VEGF (Bevacizumab Biosimilar) antibody

Catalog No. ABIN7597555

The Humanized Chimeric anti-VEGF (Bevacizumab Biosimilar) antibody has been validated for . It is suitable to detect VEGF (Bevacizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant VEGF (Bevacizumab Biosimilar) antibody (ABIN7597555)

Target: VEGF (Bevacizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Chimeric

Conjugate: This VEGF (Bevacizumab Biosimilar) antibody is un-conjugated

Application: Please inquire

Grade: Research Grade

Product Details anti-VEGF (Bevacizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Research Grade Bevacizumab Biosimilar Antibody

Specificity: Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A

Purification: Protein A or G purified from cell culture supernatant.

Purity: >95 % by SDS-PAGE.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.01M PBS, pH 7.4.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Expiry Date: 12 months

Target Details for VEGF (Bevacizumab Biosimilar)

Target: VEGF (Bevacizumab Biosimilar)

Alternative Name: Bevacizumab Biosimilar

Target Type: Biosimilar

Background: Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A

UniProt: P15692

CAS-No: 216974-75-3